Brandon Fenn represents venture capital funds and technology, biotechnology, medical device and other high-growth companies. His practice includes mergers and acquisitions, venture capital financings, public offerings and general corporate counseling.

Download full bio 

Experience

  • Immunome – $39 Million IPO 

  • Thrasio Reaches $1 Billion Valuation With Series C Financing 

  • Keros Therapeutics - $110 Million IPO 

  • Innate Pharma - $79 Million IPO 

  • Workframe Sells to Newmark Group 

  • View all

Education

  • New York University School of Law
    JD, 2010

  • Dartmouth College
    BA, 2007


Admissions & Credentials

Minnesota

New York